The article provides a detailed analysis of analyst ratings for Alnylam Pharmaceuticals, showing a shift towards somewhat bullish sentiments. The decrease in the average price target suggests tempered expectations. Despite positive revenue growth, the company's profitability and return metrics are below industry standards, which could limit short-term stock price movements.